Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 361Neoplasms 256Carcinoma, Non-Small-Cell Lung 200Colorectal Neoplasms 183Lung Neoplasms 151Prostatic Neoplasms 150Carcinoma, Hepatocellular 129Leukemia, Myeloid, Acute 96Pancreatic Neoplasms 86Multiple Myeloma 84Neoplasm Metastasis 74Recurrence 72Uterine Cervical Neoplasms 69Rectal Neoplasms 68Stomach Neoplasms 65Ovarian Neoplasms 65Triple Negative Breast Neoplasms 60Squamous Cell Carcinoma of Head and Neck 57Head and Neck Neoplasms 56Brain Neoplasms 56Glioblastoma 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Small Cell Lung Carcinoma 49Endometrial Neoplasms 46Melanoma 45Esophageal Neoplasms 43Disease 43Glioma 42Colonic Neoplasms 42Hematologic Neoplasms 41

Interventions

Trastuzumab 1Oxaliplatin 1Fluorouracil 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × HER2-positive Gastric Cancer × 1 year × Clear all
NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡